(Q45929654)

English

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

scientific article published on 14 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

1 reference

based on heuristic

inferred from title

author name string

Jun Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Dali Li

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Baocheng Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Yun Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

language of work or name

0 references

publication date

14 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

141

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

213-224

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

https://scigraph.springernature.com/pub.10.1007/s10549-013-2679-7

0 references

Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Current and emerging biomarkers in breast cancer: prognosis and prediction

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Functional antagonism between RNA binding proteins HuR and CUGBP2 determines the fate of COX-2 mRNA translation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

HuR regulates beta-tubulin isotype expression in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

MiR-200c and HuR in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

MicroRNA-125a represses cell growth by targeting HuR in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2679-7

21 January 2018

Identifiers

10.1007/S10549-013-2679-7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24036660

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45929654&oldid=2143280737"